Janelle Townes, MD
Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1801076500
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,306 of the $55,599 with a category attached, or 68.9%. 29 manufacturers reported payments, led by Lilly USA, LLC at 39.1% of the total.
Across 339 payments — averaging $164.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$22K
- Boehringer Ingelheim$15K
- Abbott$8K
- Medtronic$6K
- Novo Nordisk$1K
- Amgen$555
- plus $4K from 23 others
What the payments were for
- Consulting fees$3501%
- Speaking & faculty fees$38,30669%
- Travel & lodging$6,54712%
- Food & beverage$10,20318%
- Education$1930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 57 | $21,713 |
| Boehringer Ingelheim | 46 | $14,694 |
| Abbott | 19 | $8,171 |
| Medtronic(2 entities) | 68 | $5,710 |
| Novo Nordisk | 19 | $1,175 |
| Amgen | 22 | $555 |
| Bayer | 6 | $545 |
| Dexcom, Inc. | 15 | $522 |
| AstraZeneca | 19 | $445 |
| Corcept Therapeutics | 14 | $271 |
| BETA Bionics, Inc. | 6 | $257 |
| Sanofi-aventis U.S. LLC | 12 | $255 |
| Merck | 3 | $242 |
| Companion Medical, Inc. | 2 | $207 |
| Kowa Pharmaceuticals America, Inc. | 3 | $144 |
| Tandem Diabetes Care, Inc. | 7 | $128 |
| Shire North American Group Inc | 3 | $117 |
| Senseonics, Incorporated | 1 | $83 |
| IBSA Pharma Inc. | 4 | $66 |
| Boston Scientific | 1 | $56 |
| Insulet Corporation | 3 | $51 |
| Mannkind Corporation | 1 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Rhythm Pharmaceuticals, Inc. | 1 | $25 |
| Aegerion Pharmaceuticals, Inc. | 1 | $20 |
| AbbVie | 1 | $19 |
| Antares Pharma, Inc. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Tolmar, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$34,931
- FREESTYLE LIBRE 3$7,884
- Minimed 670G System$2,078
- MINIMED 770G$1,465
- iLet Bionic Pancreas$440
- MINIMED 780G$402
- Wegovy$361
- Kerendia$357
- Ozempic$237
- DEXCOM G6 TRANSMITTER$237
- STEGLATRO$236
- FARXIGA$124
- Repatha$122
- InPen$120
- RYBELSUS$120
- Livalo$116
- EVENITY$112
- MOUNJARO$105
How this compares
$55,599 in reported general payments places this provider in the 80th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 634 | $708,876 |
| MounjaroTirzepatide | 496 | $558,166 |
| JardianceEmpagliflozin | 294 | $241,798 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 98 | $163,088 |
| TrulicityDulaglutide | 143 | $153,501 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 161 | $146,995 |
| RybelsusSemaglutide | 54 | $65,611 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 208 | $59,478 |
| Tresiba Flextouch U-200Insulin Degludec | 60 | $50,741 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 242 | $47,453 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 39 | $44,175 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 50 | $40,151 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 60 | $39,955 |
| KerendiaFinerenone | 27 | $38,888 |
| GlyxambiEmpagliflozin/Linagliptin | 44 | $36,541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp | $1,175 | $784,517710 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev | $21,713 | $750,190730 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Glyxambi | $14,694 | $465,486549 claims |
| BayerKerendia | $545 | $38,88827 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $255 | $36,04732 claims |
| MerckJanuvia | $242 | $27,03245 claims |
| AstraZenecaFarxiga | $445 | $23,42724 claims |
| AbbVieSynthroid | $19 | $9,955160 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $7,934520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Birmingham
- Ralph TeagueBirmingham$487K
- William GarveyBirmingham$421K
- Edison GoncalvesBirmingham$142K
- Fernando BrilBirmingham$74K
- Rodrigo ValderramaBirmingham$61K
- Richard RosenthalBirmingham$24K
- Fernando OvalleBirmingham$15K
- Jennifer SohnBirmingham$14K
- Jorge PinoBirmingham$14K
- Malek KarassiBirmingham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.